การใช้ยา Sucroferric oxyhydroxide ควบคุมระดับฟอสเฟตในเลือดในผู้ป่วยโรคไตเรื้อรังที่ได้รับการบำบัดทดแทนไต Sucroferric Oxyhydroxide for the Control of Serum Phosphate in Patients with Chronic Kidney Disease

Abstract

Hyperphosphatemia is a frequent complication in patients with chronic kidney disease (CKD), primarily resulting from impaired renal phosphate excretion. Persistent elevation of serum phosphate levels, if inadequately controlled, has been associated with an increased risk of cardiovascular morbidity and mortality, as well as a decline in overall quality of life. Management strategies for hyperphosphatemia typically include dietary phosphate restriction in combination with phosphate-binding agents. Although different classes of phosphate binders exhibit comparable efficacy in reducing serum phosphate concentrations, calcium-based binders may induce hypercalcemia and promote vascular calcification, both of which contribute to an elevated risk of cardiovascular disease in CKD. Furthermore, the high pill burden associated with many phosphate binders often leads to poor treatment adherence and suboptimal phosphate control. Sucroferric oxyhydroxide, a non–calcium-based phosphate binder, offers phosphate-lowering efficacy comparable to that of conventional agents while requiring fewer tablets per day. This lower pill burden may enhance patient adherence and thereby improve phosphate management outcomes.